← Back to Search

Decision Aid Web Tool for Kidney Cancer

Led By Stella Kang, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up pre-counsel, 1 day visit
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is to study how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.

Who is the study for?
This trial is for men and women over 18 who are seeing a urologist at NYU for kidney tumors no larger than 4 cm. It's open to patients before and after surgery but not to those with stage IV cancer or anyone unable to consent.Check my eligibility
What is being tested?
The study is testing a new web tool called Decision Aid (DA) against the usual information pamphlets given by hospitals. The DA aims to help kidney tumor patients understand their treatment options better.See study design
What are the potential side effects?
Since this trial involves informational tools rather than medication, there are no direct medical side effects. However, participants may experience stress or anxiety when making treatment decisions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 18 or older with a kidney tumor no larger than 4 cm.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-counsel, 1 day visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-counsel, 1 day visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Decision Satisfaction Score
Knowledge Score
Shared Decision Making

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Decision Aid (DA) Web ToolExperimental Treatment1 Intervention
Group II: Institutional PamphletActive Control1 Intervention

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,351 Previous Clinical Trials
817,851 Total Patients Enrolled
Stella Kang, MDPrincipal InvestigatorNYU Langone Health

Media Library

Decision Aid (DA) Web Tool Clinical Trial Eligibility Overview. Trial Name: NCT05387863 — N/A
Kidney Cancer Research Study Groups: Decision Aid (DA) Web Tool, Institutional Pamphlet
Kidney Cancer Clinical Trial 2023: Decision Aid (DA) Web Tool Highlights & Side Effects. Trial Name: NCT05387863 — N/A
Decision Aid (DA) Web Tool 2023 Treatment Timeline for Medical Study. Trial Name: NCT05387863 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum allotment of participants for this experiment?

"Affirmative. According to clinicaltrials.gov, this research project is still recruiting participants and was first posted on September 12th 2022. The most recent update occurred November 4th of the same year and 213 individuals are being sought at a single site."

Answered by AI

Are there any open spots remaining for the participants of this experiment?

"Affirmative. Information found on clinicaltrials.gov shows that this medical trial, which first went live on September 12th 2022, is actively seeking participants. A total of 213 patients must be sourced from a single location."

Answered by AI
~4 spots leftby Apr 2024